Europe Plasma Fractionation Market Global Trends, Size, Developments Status and Key Players Analysis, Forecast 2028
According to a new market research study on “Europe Plasma Fractionation Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Product, Application, and End User” is expected to reach US$ 10,402.95 million by 2028 from 6,824.67 US$ million in 2021. The market is estimated to grow at a CAGR of 6.2% from 2021 to 2028. The report provides trends prevailing in the Europe plasma fractionation market along with the drivers and restraints pertaining to the market growth. Fast Market development owing to active participation of market players is the major factor driving the growth of the Europe plasma fractionation market. However, issues associated with alternate of non-plasma substitutes availability hinders the growth of Europe plasma fractionation market.
Download Sample PDF Copy: https://www.businessmarketinsights.com/sample/TIPRE00026271
The List of Companies -
- Bharat Serums and Vaccines Limited (BSV)
- Bio Products Laboratory Ltd.
- Biotest AG.
- CSL Limited
- Grifols, S.A.
- Kedrion S.p.A
- Octapharma AG
- Sanquin
- SK Plasma
The European plasma fractionation market encompasses key countries such as Germany, France, the UK, Spain, Italy, and the rest of Europe. The region holds a significant share of the global plasma fractionation market and is projected to experience robust growth over the forecast period. Factors driving this growth include an aging population, the increasing use of immunoglobulins for chronic disease treatment, a rising prevalence of immune and bleeding disorders, and the growing adoption of plasma therapies for disease management.
The treatment landscape for chronic diseases such as neurological, hematological, and respiratory disorders has evolved across Europe. The COVID-19 pandemic has influenced medical practices, as healthcare providers have prioritized critically ill patients, affecting disease diagnosis and treatment. Research organizations have also shifted their focus toward COVID-19 studies to enhance their understanding of the virus. In response, several federal agencies in the region have promoted the use of plasma therapy for COVID-19 treatment. For example, the National Agency for Medicines and Health Products Safety of France (ANSM) approved immune plasma therapy for critically ill patients, while the European Commission recommended the emergency use of convalescent plasma therapy for severe cases. This development has contributed positively to the plasma fractionation market.
However, the pandemic has also altered the medical management of neurological, hematological, and other disorders, as pharmaceutical and biopharmaceutical companies have redirected their efforts toward developing novel COVID-19 treatments. This shift has had a mixed impact on market growth, with increased use of plasma therapy for COVID-19 offset by disruptions in other therapeutic areas.
About Us:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications
Author’s Bio:
Suryakant Gadekar
Senior Market Research Expert at Business Market Insights
Comments
Post a Comment